Spotlight Innovation Inc. - FORM 10-Q

Attached files

file	filename
EX-31.2 - CERTIFICATION - Spotlight Innovation Inc.	stlt_ex312.htm
EX-31.1 - CERTIFICATION - Spotlight Innovation Inc.	stlt_ex311.htm
EX-32.1 - CERTIFICATION - Spotlight Innovation Inc.	stlt_ex321.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period ended June 30, 2015

Commission File No. 333-141060

Spotlight Innovation Inc.

(Name of small business issuer in its charter)

Nevada		98-0518266
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

6750 Westown Parkway, Suite 200-226

West Des Moines, IA 50266

(Address of principal executive offices)

(515) 274-9087

(Issuer’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated Filer	¨
Non-accelerated filer	¨	Smaller Reporting Company	x
(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of August 18, 2015, the Company had outstanding 14,277,026 shares of its common stock, par value $0.001.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2 of Part I of this report include forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by forward-looking statements.

In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "proposed," "intended," or "continue" or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other "forward-looking" information. There may be events in the future that we are not able to accurately predict or control. Before you invest in our securities, you should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline and you could lose all or part of your investment. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements
	Consolidated Balance Sheets (unaudited)	4
	Consolidated Statements of Operations (unaudited)	5
	Consolidated Statements of Cash Flows (unaudited)	6
	Notes to Consolidated Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	24
Item 4.	Controls and Procedures	24

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.	Defaults Upon Senior Securities	25
Item 4.	Mine Safety Disclosures	25
Item 5.	Other Information	25
Item 6.	Exhibits	26
Signatures		27

PART I - FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements (Unaudited)

Spotlight Innovation Inc.

Consolidated Balance Sheets

	June 30, 2015			December 31, 2014
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	1,026,224			$	9,068
Restricted cash		119,625				122,250
Prepaid expenses		35,000				-

Total current assets		1,180,849				131,318

LONG TERM ASSETS
Property, plant and equipment, net of depreciation of $1,207 and $525		30,888				8,475
In process research and development		7,119,423				6,977,347

Total assets	$	8,331,160			$	7,117,140

LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable	$	207,215			$	330,099
Accounts payable - related party		16,027				348,955
Accrued liabilities		588,193				457,440
Stock payable		-				269,705
Warrants payable		1,359,570				692,317
Line of credit, net of debt discount of $847 and $1,611 respectively		886,693				750,714
Notes payable		353,631				356,131
Short term debt - related party		166,410				183,000
Convertible debentures, net of debt discounts of $2,601,930 and $85,590, respectively		923,600				670,322

Total current liabilities		4,501,339				4,058,683

LONG-TERM LIABILITIES
Deferred liabilities		150,000				-

TOTAL LIABILITIES		4,651,339				4,058,683

Commitments and contingencies

Equity:

Series A preferred stock, $5.00 par value, 3,000,000 shares authorized, 1,051,200 shares issued and outstanding		-				-

Series C preferred stock, $5.00 par value, 500,000 shares authorized, 0 shares issued and outstanding		-				-

Preferred stock, $0.001 par value, 4,000,000 shares authorized, 0 shares issued and outstanding		-				-

Common stock, par value $0.001, 4,000,000,000 shares authorized, 13,777,026 and 13,094,618 shares outstanding		13,777				13,095
Additional paid-in capital		13,855,708				11,277,032
Accumulated deficit		(12,566,282	)			(10,601,946	)
Total equity attributable to Spotlight Innovation, Inc.		1,303,203				688,181
Non-controlling interest		2,376,618				2,370,276
Total equity		3,679,821				3,058,457

Total liabilities and equity	$	8,331,160			$	7,117,140

See accompanying notes to the unaudited consolidated financial statements.

4

Spotlight Innovation Inc.

Consolidated Statements of Operations

	For the Three Months Ended			For the Three Months Ended			For the Six Months Ended			For the Six Months Ended
	June 30, 2015			June 30, 2014			June 30, 2015			June 30, 2014
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)

REVENUE	$	-		$	-		$	-		$	-

OPERATING EXPENSES:
General and administrative expenses		759,476			252,565			1,409,011			346,409
Research and development expense		3,652			-			3,652			-
Settlement of payables		(25,908	)		-			4,076			-

Total operating expenses		737,220			252,565			1,416,739			346,409

LOSS FROM OPERATIONS		(737,220	)		(252,565	)		(1,416,739	)		(346,409	)

OTHER INCOME (EXPENSE):
Interest expense		(279,851	)		(895,511	)		(581,192	)		(914,549	)
Other income		331			-			331			-
Gain on foreign currency exchange		13,712			-			33,242			-

Total other income (expense)		265,808			895,511			547,619			914,549

Net loss		(1,003,028	)		(1,148,076	)		(1,964,358	)		(1,260,958	)
Net loss attributable to non-controlling interest holder		(1,259	)		-			(1,022	)		-

Net loss attributable to Spotlight Innovations, Inc.	$	(1,001,769	)	$	(1,148,076	)	$	(1,963,336	)	$	(1,260,958	)

Net loss per common share - basic and diluted	$	(0.07	)	$	(0.08	)	$	(0.14	)	$	(0.14	)

Weighted average number of common shares outstanding - basic and diluted		13,741,529			13,741,529			13,578,083			8,792,678

See accompanying notes to the unaudited consolidated financial statements.

Spotlight Innovation Inc.

Consolidated Statements of Cash Flows

	For the Six Months			For the Six Months
	Ended			Ended
	June 30, 2015			June 30, 2014
	(Unaudited)			(Unaudited)

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss	$	(1,964,358	)	$	(1,260,958	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount		389,257			172,312
Amortization of deferred financing costs		-			619,205
Interest expense from common shares issued for modification of convertible debt		37,500			80,000
Depletion, depreciation, amortization and accretion expense		878			-
Share-based compensation		580,209			-
Settlement of payables		4,076			-
Gain on foreign currency exchange		(33,242	)		-
Changes in operating assets and liabilities:
Prepaid expense		(35,000	)		-
Accounts payable		(106,232	)		(20,497	)
Accounts payable- related party		86,485			-
Accrued expenses		155,807			75,059
NET CASH USED IN OPERATING ACTIVITIES		(884,620	)		(334,879	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash paid for purchase of fixed assets		(5,220	)		-
Acquisition of Celtic Biotech		-			1,956
Acquisition of Memcine, net of cash received of $27,071		(2,929	)		-
Restricted cash		2,625			(40,035	)
NET CASH USED IN INVESTING ACTIVITIES		(5,524	)		(38,079	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings on short term debt		-			2,500
Proceeds from convertible debentures – related parties		1,719,800			436,205
Repayment of notes payable		(2,500	)		(100,000	)
Proceeds from sale of common stock		190,000			25,000
NET CASH PROVIDED BY FINANCING ACTIVITIES		1,907,300			363,705

NET CHANGE IN CASH		1,017,156			(9,253	)

Cash at beginning of period		9,068			19,102
Cash at end of period	$	1,026,224		$	9,849

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	$	286,163		$	-
Income tax paid	$	-		$	-

NON-CASH INVESTING AND FINANCING TRANSACTIONS
Debt discount for relative fair value of attached warrants on convertible debentures	$	277,598		$	239,190
Beneficial conversion feature for convertible debentures	$	999,310		$	197,015
Common shares issued for stock payable	$	269,705		$	-
Warrants issued in satisfaction of warrants payable	$	385,351		$	-
Warrants issued for extinguishment of accounts payable – related party	$	419,413		$	-
Common shares issued for convertible debentures	$	-		$	118,113

See accompanying notes to the unaudited consolidated financial statements.

6

SPOTLIGHT INNOVATION INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Spotlight Innovation Inc. (the “Company”) was organized under the laws of the state of Iowa on March 23, 2012 (“inception”) under the name Spotlight Innovation, LLC. In December 2013, the Company, through a reverse acquisition, merged with American Exploration Corporation (“American Exploration”). The Company was founded to identify, validate and finance healthcare-focused companies formed for the purpose of commercializing intellectual property developed by major centers of academia in the United States. The Company provides strategic partners the opportunity to participate in the financing of a preferred search for, acquisition of, and/or funding of companies holding licenses for the commercialization of intellectual property developed by academic institutions. The principals of the Company have been involved in all stages of the commercialization of healthcare intellectual property over the last eight years.

On June 4, 2014, the Company, through its subsidiary, Celtic Biotech Iowa, Inc. (“Celtic Iowa”), entered into a share exchange agreement with Celtic Biotech, Ltd., an Irish Limited Company (“CBL”), to provide for continued development and eventual marketing of the intellectual property of CBL. The primary intellectual property of CBL is an invention that relates to the compositions and methods combining snake venom toxin with chemotherapeutic agent(s) for cancer therapy. Celtic Iowa develops novel therapeutic products for the treatment of solid cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.

On June 2, 2015, the Company concluded its purchase of 82.25% ownership interest in Memcine Pharmaceuticals, Inc., a Delaware corporation, (“Memcine”) to provide for continued development of its Immunoplex™ vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response. Memcine Pharmaceuticals has a licensing agreement for its technologies with the University of Iowa.

The accompanying consolidated financial statements of Spotlight Innovation Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's latest Annual Report filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate disclosures contained in the audited financial statements for the most recent fiscal year, as reported in the Form 10-K filed with the SEC on April 15, 2015, have been omitted.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include those regarding the valuation of option and warrant transactions.

Principles of Consolidation

The consolidated financial statements include the Company’s accounts, including those of the Company’s subsidiaries Celtic Iowa and Memcine. During the year ended December 31, 2014, Celtic Iowa acquired 95% of the outstanding shares of CBL. During the three months ended June 30, 2015, the Company acquired an 82.25% interest in Memcine. Accordingly, the Company has consolidated CBL, Celtic Iowa, Inc. and Memcine. All significant intercompany accounts and transactions have been eliminated.

Non-Controlling Interest

The Company is required to report the noncontrolling interests in CBL and Memcine as separate components of shareholders’ equity. The Company is also required to present the consolidated net income and the portion of the consolidated net income allocable to the noncontrolling interest and to the shareholders of the Company separately in its consolidated statements of operations. Losses applicable to the noncontrolling interest are allocated to the noncontrolling interest even when those losses are in excess of the noncontrolling interest’s investment basis.

Loss per Common Share

Basic loss per common share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common and common equivalent shares outstanding during the period. Common share equivalents included in the diluted computation represent shares issuable upon assumed exercise of stock options and warrants or the assumed conversion of convertible debt instruments, using the treasury stock and “if converted” method. For periods in which net losses are incurred, weighted average shares outstanding is the same for basic and diluted loss per share calculations, as the inclusion of common share equivalents would have an anti-dilutive effect.

For the six months ended June 30, 2015 and 2014, the dilutive effect of 5,200 and 5,200 options and 2,992,671 and 1,833,338 warrants, and 5,215,967 and 2,009,300 common shares issuable for conversion of convertible debt, respectively, were excluded from the diluted earnings per share calculation because their effect would have been anti-dilutive.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents.

Concentrations of Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk include cash deposits placed with financial institutions. The Company maintains its cash in bank accounts which, at times, may exceed federally insured limits as guaranteed by the Federal Deposit Insurance Corporation (“FDIC”). As of June 30, 2015, the Company had $701,508 of cash balances that were uninsured. The Company has not experienced any losses on such accounts.

Foreign exchange and currency translation

For the six months ended June 30, 2015 and 2014, the Company maintained cash accounts in U.S. dollars and European Union euros, and incurred certain expenses denominated in European Union euros. The Company's and its consolidated subsidiaries’ functional and reporting currency is the U.S. dollar. Transactions denominated in foreign currencies are remeasured into U.S. dollars at exchange rates in effect on the date of the transactions. Assets and liabilities are remeasured using exchange rates at the end of each period. Exchange gains or losses on remeasurements are included in earnings.

In the event that the functional currency of a Company’s consolidated subsidiary was not the U.S dollar, then that subsidiary’s foreign currency monetary assets and liabilities are translated into U.S. dollars at the current exchange rate and non-monetary assets and liabilities are translated using historical exchange rates. Such adjustments resulting from the translation process would be reported in a separate component of other comprehensive income and are not included in the determination of the results of operations. As of June 30, 2015 and 2014, the Company had no subsidiaries with functional currencies that required translation.

In-Process Research and Development

Inprocess research and development (“IPR&D”) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&D assets acquired in a business combination are capitalized as indefinitelived intangible assets. These assets remain indefinitelived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinitelived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired. During periods after completion, those acquired indefinitelived assets are amortized based on their useful life. During 2014, the Company acquired IPR&D assets in its acquisition of CBL. The fair value of the assets acquired was $6,977,347. These assets are still subject to research and development completion and accordingly, no amortization has been recorded.

Equipment

Equipment is stated at cost less accumulated depreciation and amortization. Maintenance and repairs are charged to expense as incurred. Renewals and betterments which extend the life or improve existing equipment are capitalized. Upon disposition or retirement of equipment, the cost and related accumulated depreciation are removed and any resulting gain or loss is reflected in operations. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which is 10 years.

Impairment of Long-Lived Assets and Intangibles

The Company performs impairment tests on its long-lived assets when circumstances indicate that their carrying amounts may not be recoverable. If required, recoverability is tested by comparing the estimated future undiscounted cash flows of the asset or asset group to its carrying value. If the carrying value is not recoverable, the asset or asset group is written down to fair value. For the three months ended June 30, 2015 and 2014, the Company recorded $0 in impairment to the Company’s long-lived assets.

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for stock and stock options based on the grant date fair value of the awards. The Company determines the fair value of stock option grants using the Black-Scholes option pricing model. The Company determines the fair value of shares of non-vested stock (also commonly referred to as restricted stock) based on the last quoted price of our stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates, if historical forfeiture rates are available. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.

Income Taxes

The Company utilizes the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for operating loss and tax credit carry-forwards and for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that the value of such assets will be realized.

Fair Value of Financial Instruments

The Company follows FASB ASC 820, Fair Value Measurement (“ASC 820”), which clarifies fair value as an exit price, establishes a hierarchal disclosure framework for measuring fair value, and requires extended disclosures about fair value measurements. The provisions of ASC 820 apply to all financial assets and liabilities measured at fair value.

As defined in ASC 820, fair value, clarified as an exit price, represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a result, fair value is a market-based approach that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value.

	Level 1 – Quoted prices in active markets for identical assets or liabilities.

	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Subsequent Events

The Company evaluated subsequent events through the date when financial statements are issued for disclosure consideration.

Recent Accounting Pronouncements

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.

NOTE 3. GOING CONCERN

The Company is an early stage company and as such has not generated revenues from operations and there is no assurance of any future revenues. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of June 30, 2015, the Company has accumulated net losses of $12,566,282 and has a working capital deficit $3,320,490. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.

The ability of the Company to continue as a going concern is dependent upon the Company’s successful efforts to raise sufficient capital and then attain profitable operations. Management is investigating all options to raise enough funds to meet the Company’s working capital requirements through either the sale of the Company’s common stock or other financings. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company.

NOTE 4. ACQUISITIONS

Memcine

On June 2, 2015, the Company acquired 82.25% of the ownership in Memcine for $30,000.

The following table summarizes the allocation of the purchase price to the net assets acquired:

Fair value at June 2, 2015
Cash	$	27,071
Property, plant and equipment		18,071
IPR&D		142,076
Total assets		187,218

Accounts payable and accrued liabilities		(854	)
Deferred liabilities		(150,000	)
Total liabilities		(150,854	)
Net assets acquired	$	36,364

The Company recorded the 17.75% non-controlling interest in Memcine at a fair value of $6,364.

Memcine had immaterial activity during the six months ended June 30, 2015. Accordingly, the Company has not presented Pro forma information for the acquisition as the impact to the Company’s operations was deemed immaterial.

CBL

In June 2014, the Company, through its wholly-owned subsidiary Celtic Iowa, entered into a share exchange agreement with CBL. Celtic Iowa issued 474,419 shares of its Preferred B Stock, par value of $5.00 per share. In exchange, the Company received shares equal to 95% of the total outstanding shares of CBL.

As there is no existing market for the preferred shares of Celtic Iowa, the Company used the fair value of the acquired net assets of CBL to determine the purchase price. The following table summarizes the allocation of the purchase price to the net assets acquired:

Fair value at June 4, 2014
Cash	$	1,656
Accounts receivable – related party		1,349
Property, plant and equipment		9,000
IPR&D		6,977,347
Total assets		6,989,352

Accounts payable and accrued liabilities		(242,693	)
Short-term debt – related party		(204,186	)
Total liabilities		(446,879	)
Final Purchase price	$	6,542,473

The Company recorded the 5% non-controlling interest in CBL at a fair value of $327,124. The preferred shares issued are convertible into common shares of Celtic Iowa on a one for one basis in the event of a Deemed Liquidation Event (as defined in the Certificate of Designation) and are redeemable at the Company’s option in five years at the stated par value of $5 per share. The preferred shares have preferential rights to the net assets of Celtic Iowa in the case of liquidation up to the par value of the stock. While the Company maintains voting control through the common stock of Celtic Iowa and controls management decisions of Celtic Iowa, the Company’s rights to the net assets are subordinated to the preferred stock until the net assets of the Company exceeds $2,372,078. As a result, the Company has recorded non-controlling interest in Celtic Iowa of $2,372,078, which is the value attributed to the Preferred B stock issued by Celtic Iowa net of the non-controlling interest in CBL. The Preferred Stock of Celtic Iowa is eliminated in consolidation.

CBL had immaterial activity during the six months ended June 30, 2014. Accordingly, the Company has not presented Pro forma information for the acquisition as the impact to the Company’s operations was deemed immaterial.

NOTE 5. NOTES PAYABLE

On December 16, 2013, the Company assumed the liabilities of American Exploration which included the following notes payable to unrelated third parties:

	Date	Stated			Original
	of	Interest			Principal		Due
Promissory Note	Note	Rate			Amount		Date	Default

#1	05/29/09		10	%	$	30,000	On Demand	No
#2	06/05/09		10	%	$	7,698	On Demand	No
#3	08/16/09		10	%	$	50,000	On Demand	No
#4	09/27/10		10	%	$	60,000	On Demand	No
#5	06/02/10		5	%	$	50,000	On Demand	No
#6	02/04/11		5	%	$	30,000	On Demand	No
#7	05/04/11		5	%	$	35,000	On Demand	No
#8	08/11/11		10	%	$	20,000	On Demand	No
#9	12/05/11		10	%	$	20,000	On Demand	No
#10	04/28/12		10	%	$	30,000	On Demand	No

The Company also assumed $97,436 in accrued interest related to these notes. The Company recorded $14,360 and $14,353 in interest expense for the six months ended June 30, 2015 and 2014, respectively, on the above notes payable.

The Company also assumed a liability for previous advances made by American Exploration’s former CEO in the amount of $23,433. During the six months ending June 30, 2015, the Company repaid $2,500 of these advances. These advances are due on demand and do not bear interest.

During the six months ended June 30, 2014, the Company received advances from a third party in the amount of $2,500. These advances were due on demand and did not bear interest, and have been repaid as of June 30, 2015.

As of June 30, 2015 and through the date of these financial statements, the Company has not received any demand notice from the lenders noted above for payment of principal or interest on these notes payable.

NOTE 6. CONVERTIBLE INSTRUMENTS

Kopriva Note

On September 27, 2013, the Company entered into a convertible note (the “Kopriva Note”) in the amount of $40,000 from an investor. The term of the Kopriva Note is fifteen months from commencement. During the term of the Kopriva Note, interest shall accrue on the unpaid principal balance at a fixed rate equal to 10% per annum, compounded annually. Should the Company default on the Kopriva Note, the outstanding balance of the Kopriva Note shall bear interest at the default rate of 20% per annum, compounded annually. In addition to the interest accrued the holder received warrants to purchase up to 100,000 shares of common stock. The conversion feature of the Kopriva Note and the exercise price of the warrants is the greater of (i) a discount of 40% to the 20 day average closing market price prior to the day that the warrant is executed or (ii) $0.20 per share. The warrants will have a term of thirty-six (36) months from the date of repayment or conversion of the Kopriva Note. The relative fair value of the warrants issued on the date of grant was $25,136 and was recorded as a debt discount on the Kopriva Note.

In connection with the Kopriva Note, the conversion feature was also analyzed for a beneficial conversion feature at which time it was concluded that a beneficial conversion feature existed. The Company recorded a debt discount of $14,864 for the fair value of the beneficial conversion feature. The Company amortized the combined debt discounts from the warrants and beneficial conversion feature over the term of the Kopriva Note.

On December 19, 2014, the Company entered an agreement to extinguish the Kopriva Note and its accrued interest in exchange for 100,002 shares of common stock. This agreement modified the terms of the conversion which resulted in the holder receiving more shares. As a result of the modification of the conversion feature, the Company determined that the change in the fair value of the conversion feature was greater than 10% and accordingly, recorded $120,085 as a loss on debt extinguishment which was the difference in fair value of the new conversion feature and the carrying value of the Kopriva Note and accrued interest on the date of modification. The Company recorded the issuance of the common stock on conversion at its fair value of $165,003 based on the market price on the date of grant.

Convertible Debt Associated with Line of Credit

On April 4, 2014, the Company entered into a line of credit (the “Line of Credit”) with Denver Savings Bank in the principal amount of $752,325. The Line of Credit provides that the Company can borrow up to the aforementioned principal amount from the bank until April 1, 2017, subject to the borrowing occurring as prescribed by the Security and Loan Agreement as described below. Interest accrues at the rate of 4.25% per year. The loan is repayable on demand, but if no demand is made, then quarterly payments of accrued interest calculated on the amount of credit outstanding. As security for the Line of Credit a third party (the “Cosigner”) cosigned the Line of Credit, and pledged certain collateral. In exchange for this pledge, the Company issued to the Cosigner 150,000 shares of common stock of the Company, and agreed to issue 30,000 shares of its common stock upon each one year anniversary of the Line of Credit, provided that the Line of Credit remains in effect. The shares of common stock had a fair value of $183,000 based on the market price on the date of grant and have been recorded as interest expense.

On April 4, 2014, the Cosigner and three third parties entered into a Security and Loan Agreement (the “SLA”). The SLA ensures that the Cosigner will be fully remunerated should the Company default on the Line of Credit. The SLA provides a guaranty to the Cosigner from the three third parties, which have pledged to repay any outstanding amounts on the Line of Credit should the Company default on the Line of Credit.

The Company may request draw downs on the Line of Credit at any time. Once a request is made, the Cosigner withdraws the funds and issues them to the third parties. The third parties will then loan the Company the funds from the Line of Credit and the Company issues convertible promissory notes (the “Convertible Notes”). As the Company is both obligated to the Bank, as primary obligor, and to the third parties through the Convertible Notes, the Company has recorded liabilities on both obligations. The amounts attributable to the Line of Credit directly are recorded as non-cash interest expense. As of June 30, 2015, the Company had borrowed $752,325 through the Line of Credit, and issued Convertible Notes with the third parties in the amount of $752,325. The Convertible Notes accrue interest at 20.5% per annum and mature in six months from the dates of issuance. The Company received $572,220 in net proceeds from the Convertible Notes, net of debt service, expense fees and legal fees. These fees were recorded as a debt discount on the Convertible Notes. The Convertible Notes also contain a conversion feature which allows the Company to convert the Convertible Notes into shares of the Company’s common stock. The conversion price is the lower of 50% of the prior 20 days average market price on the date of conversion, or $0.50 per share. However, in no event will the conversion price be lower than $0.25 per shares. The Company analyzed the Convertible Notes for a beneficial conversion feature. As a result of the in-the-money conversion price, the Company determined that a beneficial conversion feature did exist and recorded a debt discount of $186,869.

Pursuant to the Convertible Notes, the Company issued warrants to purchase 752,325 shares of common stock of the Company at an exercise price equal to the lower of: (i) 50% of the prior 20 days average market price on the date of exercise, or (ii) $0.50 per share. However, in no event will the exercise price be lower than $0.25 per share. The warrants have a term of three years. The Company calculated the relative fair value of the warrants using the Black-Scholes model at $385,351, which was recorded as a debt discount to the Convertible Notes.

All notes were due on December 31, 2014 and are now in default. The Company has not received a notice of default or demand for repayment from the lenders as of the date of this filing.

Additional Convertible Notes Associated with Additional Line of Credit

On July 29, 2014, the Company entered into an agreement with a third party individual to guarantee an additional line of credit (the “Additional Line of Credit”) in the amount of $250,000 with Denver Savings Bank. The Company may request draw downs on the Additional Line of Credit at any time. In exchange for the guarantee, the Company issued 42,300 shares of its common stock to the Individual. The shares of common stock had a fair value of $33,840 based on the market price on the date of grant and have been recorded as deferred financing costs.

The Individual and three third parties entered into a Security and Loan Agreement (the “Additional SLA”). The Additional SLA ensures that the Individual will be fully remunerated should the Company default on the Additional Line of Credit. The Additional SLA provides a guaranty to the Individual from the three third parties, which have pledged to repay any outstanding amounts on the Additional Line of Credit should the Company default on the Additional Line of Credit.

As of June 30, 2015, $135,000 has been drawn on the Additional Line of Credit. Once a request is made, the Individual withdraws the funds and issues them to the third parties. The third parties then loan the Company the funds from the Line of Credit and the Company issues convertible promissory notes (the “Additional Convertible Notes”). The third party guarantors require the Company to repay all funds drawn under the Additional Line of Credit to the bank in addition to the obligation to pay the guarantors for the principal amount of the convertible notes. As the Company is both obligated to the Bank, as a cosigner to the Additional Line of Credit and to the third parties through the Additional Convertible Notes, the Company has recorded liabilities on both obligations.

The Company has entered into Additional Convertible Notes with the third parties in the amount borrowed. The Additional Convertible Notes accrue interest at 20.5% per annum and mature in six months from the dates of issuance. The Convertible Notes contain a conversion feature which allows the Company to convert the Additional Convertible Notes into shares of the Company’s common stock. The conversion price is the lower of 50% of the prior 20 days average market price on the date of conversion, or $0.50 per share. However, in no event will the conversion price be lower than $0.25 per share. The Company analyzed the Convertible Notes for a beneficial conversion feature. As a result of the in-the-money conversion price, the Company determined that a beneficial conversion feature did exist and recorded a debt discount of $31,815.

Pursuant to the Additional Convertible Notes, the Company issued warrants to purchase 135,000 shares of common stock of the Company at an exercise price equal to the lower of: (i) 50% of the prior 20 days average market price on the date of exercise, or ii) $0.50 per share. However, in no event will the exercise price be lower than $0.25 per share. The warrants have a term of three years. The Company calculated the relative fair value of the warrants using the Black-Scholes model at $67,985, which was recorded as a debt discount to the Convertible Notes.

The Company is amortizing the combined debt discounts from the original issue discounts, warrants and beneficial conversion feature over the term of the Convertible Notes and Additional Convertible Notes. The Company recorded interest expense of $201,298 related to the amortization of the debt discounts for the six months ended June 30, 2015. The Company also recorded $103,535 in interest expense for the three months ended June 30, 2015.

Greig Companies Note

On March 27, 2015, the Company entered into a convertible note (the “Greig Note”) in the amount of $2,500,000 with a related party investor and received proceeds of $1,620,000, net of debt service, origination fee and legal fees. The term of the Greig Note is sixty months from commencement. During the term of the Greig Note, interest shall accrue on the unpaid principal balance at a rate equal to the prime rate plus five percentage points per annum, compounded annually, for the first thirty-six months; and prime rate plus six percentage points in the last twenty-four months. Should the Company default on the Greig Note, the outstanding balance of the Greig Note shall bear interest at the default rate of two additional percentage points per annum, compounded annually. The Company issued warrants to purchase 250,000 and 300,000 shares of the Company's common stock to K4, LLC and The Grieg Companies, respectively, as consideration for entering into the convertible note. The warrants have an exercise price equal to 50% of the 20 day average closing market price of the Company’s common stock prior to the date of exercise, provided that the exercise price shall not be below $1.50 per share. The Greig Note also contains a conversion feature that allows the investor to convert the unpaid principal and accrued interest into shares of the Company’s common stock at a price of $1.50 per share. The warrants will have a term of thirty-six (36) months from the date of repayment or conversion of the Greig Note. The relative fair value of the warrants issued on the date of grant was $652,504 and was recorded as a debt discount on the Greig Note. As of June 30, 2015, the Company has recorded the relative fair value as a warrant payable. The Company analyzed the Greig Note for a beneficial conversion feature. As a result of the in-the-money conversion price, the Company determined that a beneficial conversion feature did exist and recorded a debt discount of $967,496.

The Company is amortizing the combined debt discounts from the original issue discounts, warrants and beneficial conversion feature over the term of the Convertible Notes. The Company accrued interest expense of $53,682 and recorded amortization of the debt discount as interest expense for $52,960 during the six months ended June 30, 2015.

NOTE 7. DEFERRED LIABILITIES

In September 2012, Memcine received financial assistance from Iowa Economic Development Authority (“IEDA”). Memcine entered into an agreement with IEDA, whereby IEDA would provide $150,000 in cash proceeds to Memcine in exchange for a 2% royalty on future gross revenues of Memcine to be paid to IEDA as repayment for the financial assistance. Total royalties to be paid will be $225,000 and the payment terms are on a semi-annual basis. To date Memcine has not produced any revenues and has not been obligated to make repayment of the financial assistance. The contract also includes an acceleration clause which would require the Company to make a lump sum repayment of the financial assistance plus accrued interest at 6% per annum beginning from the date the proceeds were disbursed to Memcine should any of the following occur:

a)	Memcine issues an initial public offering

b)	Memcine relocates outside of the state of Iowa

c)	Memcine sells 51% or more of the company’s assets or the company

As a condition to the acquisition by the Company, Memcine applied and was granted a waiver of the acceleration clause. Accordingly, the future repayment obligation is recorded as a long term deferred liability.

NOTE 8. INCOME TAXES

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income.

At June 30, 2015, the Company’s deferred tax assets consisted primarily of net operating loss carry forwards acquired from American Exploration in the merger. For the three months ended June 30, 2015, the material reconciling items between the tax benefit computed at the statutory rate and the actual benefit recognized in the financial statements consisted of expenses related to sharebased compensation and the change in the valuation allowance during the applicable period. At June 30, 2015, the Company has recorded a 100% valuation allowance as management believes it is likely that any deferred tax assets will not be realized.

As of June 30, 2015, the Company had a net operating loss carry forward of approximately $11.8 million, which will expire between years 2028 and 2035. Due to the change in ownership provisions of the Tax Reform Act of 1986, the net operating loss carry forwards are expected to be subject to significant annual limitations for the change in ownership that resulted in the Company’s merger with American Exploration, Inc in the year ended December 31, 2013.

NOTE 9. EQUITY

The Company has authorized the issuance of 500,000 shares of Series A preferred stock, 500,000 shares of Series C preferred stock, 4,000,000 shares of other preferred stock and 4,000,000,000 shares of other common stock.

COMMON STOCK

2015 Issuances

On January 5, 2015, the Company issued 33,334 shares of common stock for a subscription received in December 2014. The subscription consisted of 33,334 shares of common stock and 12,500 warrants to purchase one share of common stock for each warrant, for net cash proceeds of $25,000. The warrants have an exercise price of $1.25 per share and expire three years after the date of issuance. The relative fair value of the common stock was $13,702 and was recorded as a stock payable as of December 31, 2014. As of March 31, 2015, the warrants remain unissued.

In January 2015, the Company issued 157,000 shares of its common stock to settle stock payables in an amount of $256,002.

On February 3, 2015, the Company issued 25,000 shares of its common stock to a consultant with a professional services agreement. The shares were valued at $41,250, based on the market price on the date of grant and were recorded as compensation expense.

On February 28, 2015, the Company entered into a stock for services agreement with Michael Reysack, the Company’s Investor Relations Officer, to issue 156,139 shares of common stock for services. The fair value of these shares was $257,629 based on the market price on the date of grant.

In February 2015, the Company issued several subscription units that consisted of common stock and warrants. The Company received subscriptions to acquire 113,335 shares of common stock and 42,500 warrants to purchase one share of common stock for each warrant, for net cash proceeds of $85,000. The warrants have an exercise price of $1.25 per share and expire three years after the date of issuance.

On April 3, 2015, the Company received a subscription for 140,000 shares of common stock and warrants to purchase 52,500 shares of common stock for each warrant, for net cash proceeds of $105,000. The warrants have an exercise price of $1.25 per share and expire three years of the date of issuance. The relative fair value of the warrants calculated based on the Black-Scholes model was $40,368.

On April 28, 2015, the Company issued 30,000 shares to a third party in conjunction with the annual line of credit fee with Denver Savings Bank. The shares were valued at $37,500, based on the market price on the date of grant and will be recorded as interest expense.

On April 28, 2015, the Company issued 2,600 shares to a third party in conjunction with a professional services agreement entered into on December 19, 2014. The shares were valued at $3,250, based on the market price on the date of grant and is recorded as compensation expense.

On June 6, 2015, the Company issued 25,000 shares to a third party in conjunction with a professional services agreement entered into on December 19, 2014. The shares were valued at $31,250, based on the market price on the date of grant and is recorded as compensation expense.

Options

We have one equity compensation plan, the Spotlight Innovation Inc. 2009 Stock Option Plan (the “2009 Plan”).

A summary of the stock option activity for the six months ended June 30, 2015 is presented below.

	Options		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding December 31, 2014		5,200	$	359.04	$	-
Granted		-		-		-
Exercised		-		-		-
Expired		-		-		-
Outstanding June 30, 2015		5,200	$	359.04	$	-
Exercisable June 30, 2015		5,200	$	359.04	$	-

Warrants

During the three months ended March 31, 2015, the Company received subscriptions to acquire 113,335 shares of common stock and 42,500 warrants to purchase one share of common stock each, for net cash proceeds of $85,000. The warrants have an exercise price of $1.25 per share, and expire three years of the date of issuance. The relative fair value of the warrants based on the Black-Scholes model was $38,413. As of June 30, 2015, the Company has recorded the relative fair value as a warrant payable.

The Company issued warrants to purchase 135,000 shares of common stock in conjunction with the Additional Convertible Notes during January 2015. The exercise price is equal to the lower of: (i) 50% of the prior 20 days average market price on the date of exercise, or ii) $0.50 per share. However, in no event will the exercise price be lower than $0.25 per share. The warrants have a term of three years. The relative fair value of the warrants based on the Black-Scholes model was $67,985.

The Company granted warrants to purchase 250,000 and 300,000 shares of common stock to related parties in conjunction with a convertible note dated March 27, 2015. The warrants have an exercise price of $1.50 per share, and expire thirty-six (36) months from the date of repayment or conversion of the convertible note. The relative fair value of the warrants based on the Black-Scholes model was $652,504. As of June 30, 2015, the Company had issued warrants to purchase 300,000 common shares and recorded the relative fair value of the unissued warrants of $277,598 as a warrant payable.

The Company issued warrants to purchase 359,620 shares of common stock to a related party in conjunction with a settlement of an outstanding payable in the amount of $419,413. The warrants have an exercise price of $1.50 per share, and expire five years from the date of issuance. The fair value of the warrants based on the Black-Scholes model was $449,398. Accordingly, the Company recorded a loss on extinguishment of debt of $29,984. As of June 30, 2015, the Company has recorded the relative fair value as a warrant payable.

The fair value of the above warrants was determined by using the BlackScholes optionpricing model. Variables used in the model for the warrants issued include: i) discount rates ranging from 1.07% to 1.42%; ii) expected terms ranging from 3.00 to 5.00 years; iii) expected volatility ranging from 328.77% to 406.58%; iv) zero expected dividends and v) stock price of $1.25 to $1.65.

During the six months ended June 30, 2015, the Company issued 862,500 warrants that were granted in the year ended December 31, 2014 and were recorded as a warrant payable. The Company recorded $561,573 in additional paid-in capital for the issuance of the warrants in satisfaction of the warrants payable.

A summary of the warrant activity for the six months ended June 30, 2015 is presented below:

	Warrants		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding December 31, 2014		1,364,171	$	1.40	$	-
Granted		1,354,969		1.25		-
Exercised		-		-		-
Expired		-		-		-
Outstanding June 30, 2015		2,719,140		1.94		-
Exercisable June 30, 2015		2,719,140		1.94	$	-

The weighted average remaining contractual term of the outstanding warrants and exercisable warrants as of June 30, 2015 is 3.27 years.

NOTE 10. COMMITMENTS AND CONTINGENCIES

On June 4, 2014, the Company entered into a series of agreements related to an equity arrangement for the sole purpose of funding acquisitions. The Company issued 1,051,200 Convertible Series A Preferred stock for $41,418,000 to nine investors, through a private placement of 900 Units (the “Securities”) consisting of 1,051,200 shares of Convertible Series A Preferred Stock (convertible into common shares of the Company) and warrants to purchase 413,964,900 common shares of the Company. The warrants have exercise prices from $0.25 to $0.7035 per share and terms of four to six years. The Company can receive up to $165,681,009 if all the warrants are exercised. The Convertible Series A Preferred stock may convert into common shares of the Company at a rate of 1 share of Series A Preferred stock for 100 shares of common stock and must be converted within three years.

Under the terms of the Unit Subscription Agreement (USA), the Investors' cash of $41,418,000 ($46,020 per Unit sold) has been deposited in a restricted account with an Intermediary, whereby an Account Management Agreement (AMA) between the Investors, the Company, and the Intermediary governs the release of funds to the Company from the restricted account. The Company has placed with the Intermediary, the Securities to be released to the investors at the same time and ratio as the funds are released to the Company upon each closing (as defined in the USA). The Company will record the fair value of the Securities as they are issued to the investors by the Intermediary.

The restricted cash will be released to the Company with the approval of the Investors. A request first must be made to the Investors' representative along with a Use of Proceeds (UOP) and, after review and approval by Investors' representative, will the funds be released. There are 36 planned periodic installments pursuant to the AMA schedule, which have already been approved by the Company and the Investors.

The release of funds is based upon trading volumes at or above a minimum bid price which will cause a release of a percentage of each periodic “Breakout” funds to the Company. There are provisions within the agreement which address release of funds to the Company in the event that:

	1.)	trading volume is below the minimums, and

	2.)	average bid prices are above or below the minimums.

As of June 30, 2015, the Company has not had any funds released to it. As such, the Securities are still in escrow.

The Company, through its subsidiary Celtic Biotech Iowa, Inc. entered into a license agreement to license technology for novel therapy for chronic kidney disease owned by Zheng-Hong Qin of Wilmington, Massachusetts. The agreement provides for a 7% royalty payment on all net sales related to the licensed therapies. As of June 30, 2015, no sales have been made.

On December 3, 2014, the Company signed a Memorandum of Understanding with Black Swan, LLC to provide certain government relations and related services. The MOU provides for compensation to Black Swan of a monthly cash retainer as well as a grant of 150,000 common shares at a date that is mutually agreed upon by the parties:

	(1)	A monthly retainer, the amount and duration of which to be determined, but in any event a total of $7,500 shall be paid to Black Swan for initial work during the period ending December 31, 2014 ($3,750 of which has previously been paid by the Company to Black Swan);

	(2)	A grant of equity in the amount of 150,000 shares, or the equivalent options with a strike price of $1.00, or other functionally equivalent interest in the Company with a current market value of $250,000; and

	(3)	An increase in the monthly retainer or a bonus payment equal to 10% of private money and 6% of public money received by the Company or its subsidiaries through introductions provided by Black Swan to the Company.

On December 19, 2014, the Company entered into an agreement with a third party to provide investor relations consulting services. The Company agreed to issue 25,000 shares of restricted common stock at the time of the agreement and up to 150,000 additional shares based on milestones achieved by the consultant. As of December 31, 2014, the consultant had achieved one of the milestones and was due an additional 25,000 shares. The fair value of the 55,000 shares of common stock to be issued to the consultant was $91,000 based on the market price on the dates of grant which was recorded as a stock payable at December 31, 2014. During the three months ended March 31, 2015, the consultant met an additional milestone which required the Company to issue 25,000 shares of common stock. The shares were valued at $41,250 based on the market price on the date grant. All of the shares earned by the consultant were issued in January and February of 2015. On April 29, 2015, the consulting agreement was mutually terminated. As a result of the termination of the agreement, 100,000 warrants were cancelled.

On April 29, 2015, the Company entered into a three-year consulting agreement with Sundrop Consulting, Inc. (“Sundrop”) and agreed to compensate Sundrop as follows: $10,669 per month; 25,000 shares of common stock upon execution of the agreement; a warrant to purchase 100,000 shares of the Company’s common stock at $1.29 per share with an expiration date of December 19, 2017. In addition, the Company agreed to pay a bonus of $300,000 in cash and 500,000 shares of common stock if the Company receives $10 million in financing through the efforts of Sundrop; a bonus of $100,000 in cash and 300,000 shares of common stock if the Company achieves a listing of its securities on the New York Stock Exchange or Nasdaq; and a bonus of $750,000 in cash and 1.5 million shares of common stock if the Company receives $40 million in financing through the efforts of Sundrop.

NOTE 11. RELATED PARTY TRANSACTIONS

As a result of the acquisition of CBL, the Celtic Biotech Iowa, Inc. assumed two short-term notes payable due to a related party. The debts are denominated in Euros, and on June 4, 2014, the date of acquisition, the carrying amount of the debts were $204,186 after foreign currency remeasurement. The notes accrue compounded interest at 5% per annum and were due in November and December 2014. As of June 30, 2015, these notes were still outstanding and the carrying value of the notes was $166,410, resulting in the Company recording $16,690 in gain on foreign currency remeasurement. The Company has negotiated an extension of the due date to December 31, 2015 for the note that was due in December 2014.

On March 27, 2015, the Company entered into an agreement with Catwalk Capital, LLC to settle outstanding fees due to Catwalk. To settle a balance of $491,881, the Company agreed to pay $72,467 in cash and the Company granted Catwalk 359,620 warrants to purchase common shares of the Company at $1.25 per share, expiring five years after date of issuance. The warrants have an exercise price of $1.50 per share, and expire five years from the date of issuance. The fair value of the warrants based on the Black-Scholes model was $449,398. Accordingly, the Company recorded a loss on extinguishment of debt of $29,984.

On March 30, 2015, the Company entered into a consulting agreement with The Greig Companies, whose principal is a significant shareholder of the Company. The consultant will provide corporate and strategic growth advisory services. The Company has agreed to pay the consultant a $10,000 monthly fee with an additional per diem reimbursement of $1,250 for days traveling. The term of the contract is 3 years.

NOTE 12. SUBSEQUENT EVENTS

On July 1, 2015, Celtic Biotech Iowa received a communication from Instituto Buhtantan indicating that they have licensed its patent application entitled “Methods, kits and compositions comprising crotamine”, among other patent applications and patents, which are now in the name of Research Support Foundation of the State of São Paulo – FAPESP. Celtic Biotech Iowa has agreed to pay $15,000 upon receipt of an invoice and an additional $15,000 sixty days thereafter.

On July 1, 2015, the Company entered into an agreement with DAK Capital, LLC to provide investment banking and capital advisory services in connection with the Company’s efforts to raise approximately $10 million in capital and with respect to such other matters as to which the Company and DAK may agree. The agreement has a minimum term of six months and a monthly non-refundable payment of $10,000 to DAK. In the event that DAK completes a transaction for the benefit of the Company of at least $10 million during this six month term, the agreement is automatically extended for eighteen additional months. Each transaction is subject to payment of a success fee of 8% to DAK, as well as warrants equal to the amount of the transaction, each with a term of five years.

On July 14, 2015, CBL entered into a clinical agreement with Immunoclin, Ltd., a United Kingdom corporation, to carry out the phase 1b (and potentially phase 2) trial of the drug Crotoxin. The agreement calls for Celtic Biotech to pay euros to Immunoclin, Ltd. 525,330 (approximately $584,908) over the period of the trial, which is expected to last 18 months.

On July 15, 2015, the Company issued 500,000 shares of common stock to a third party in conjunction with a professional services agreement entered into on April 29, 2015. The shares were valued at $625,000, based on the market price on the date of grant and will be recorded as professional fees expense.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Background

Spotlight Innovation Inc. (the “Company” or “We”) was organized under the laws of the state of Iowa on March 23, 2012 (“inception”) under the name Spotlight Innovation, LLC. In December 2013, the Company, through a reverse acquisition, merged with American Exploration Corporation (“American Exploration”). The Company was founded to identify, validate and finance healthcare-focused companies formed for the purpose of commercializing intellectual property developed by major centers of academia in the United States. The Company provides strategic partners the opportunity to participate in the financing of a preferred search for, acquisition of, and/or funding of companies holding licenses for the commercialization of intellectual property developed by academic institutions. The principals of the Company have been involved in all stages of the commercialization of healthcare intellectual property over the last eight years.

Business

We provide solutions for healthcare-focused companies commercializing healthcare intellectual property developed by major centers of academia in the United States. We focus on identifying, validating and acquiring/cooperating with early stage companies developing healthcare technologies including pharmaceuticals, devices and equipment, diagnostic products and healthcare IT. We place a premium on identifying and targeting disruptive healthcare IP — intellectual property technology with the potential to transform by changing core value propositions and competition in the healthcare industry, and generating the greatest positive impact on the health and well-being of as many people as possible.

We combine innovative thinking with the proven ability to:

	·	Identify categories of IP that have the attributes of future growth, scalability and profit potential

	·	Provide accurate, defensible and actionable business analysis

	·	Identify existing healthcare IP companies with significant growth potential

	·	Time entry into each category based on technological and cultural readiness

	·	Identify and overcome barriers to successful commercialization and adoption

	·	Implement repeatable processes that bring speed, accuracy and efficiency to commercialization

We engage proactively with our portfolio companies by providing oversight, strategic direction, serving on boards, and business development assistance. We drive our portfolio companies for all stakeholders, including entrepreneurs, management, investors and employees. We are building a portfolio of healthcare/life sciences companies, each having the potential to positively impact the health, well-being and longevity of an enormous number of lives.

On June 4, 2014, the Company, through its subsidiary, Celtic Biotech Iowa, Inc. (“Celtic Iowa”), entered into a share exchange agreement with Celtic Biotech, Ltd., an Irish Limited Company (“CBL”), to provide for continued development and eventual marketing of the intellectual property of CBL. The primary intellectual property of CBL is an invention that relates to the compositions and methods combining snake venom toxin with chemotherapeutic agent(s) for cancer therapy. Celtic Biotech Iowa develops novel therapeutic products for the treatment of solid cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.

Celtic Iowa holds a license related to Cardiotoxin, a drug currently in Phase 1 trials. If clinical efficacy for Cardiotoxin can be demonstrated in chronic kidney disease then it would represent the only specific product for this condition. Clinical studies are expected to be relatively straightforward to organize and the clinical endpoints well established. A small trial could be completed to establish the baseline response prior to committing to full scale studies. We could see studies well underway before 2015 year end with a Federal Drug Administration (“FDA”) trial wrapped up by end of fiscal 2016. The application is patent pending and would meet New Chemical Entity status in the United States (“US”) and European Union (“EU”).

Celtic Iowa is engaged in clinical trials in France and it anticipates restarting a study previously begun by CBL prior to being acquired by the Company. In order to monitor the trial per regulatory requirements they have a Contract Research Organization (CRO) in place (Immunoclin). The study drug is available for the study, however, given the period of time since its manufacture it needs to be retested for potency. If adequate potency cannot be confirmed then a new study drug batch will need to be prepared.

In March, 2015 Celtic Iowa registered and launched a topical gel product as a drug delivery base for use in pharmacy compounding. The concept allows Celtic Iowa to enter the market place and may start generating some small revenues to assist in fueling the burn rate. At this time no sales have been made though efforts will increase in the near future.

Along with this effort, the Company is assessing a similar formulation to assess if the product may be useful in treating precancerous skin lesions.

Memcine Pharmaceuticals, Inc.

On June 2, 2015, the Company entered into a Securities Purchase Agreement with Memcine Pharmaceuticals, Inc. (“Memcine”). Pursuant to the agreement the Company will acquire approximately 82.25% of the outstanding securities of Memcine.

Memcine Pharmaceuticals, Inc. is a universal vaccine platform company founded in 2010 to develop Immunoplex™, with broad applicability in both infectious diseases and oncology immunotherapy. Immunoplex™ infectious disease vaccines are delivered needle-free at mucosal surfaces without adjuvants, and elicit a more robust immune response via the body’s natural immune defenses. Immunoplex™ vaccines are protein subunit-based, and therefore avoid the manufacturing and distribution hurdles normally associated with infectious agent-based vaccines. Proof-of-concept has been achieved in several murine models, including Hepititus B, influenza, and a breast cancer immunotherapy model. Memcine’s business strategy is to function as a discovery engine and out-license by field and territory.

Immunoplex™ utilizes a universal antibody in all vaccines for both infectious diseases and oncology personalized medicine indications. The crux of the invention involves a proprietary peptide tag that is covalently attached to the antigen or tumor cell, and an antibody that binds the tag to form an “Immunoplex”. The tag-antibody complex delivers the antigen cargo to key immune players such as dendritic cells and macrophages. Thus the immune system is efficiently alerted, utilizing far less antigen than traditional vaccines and without harmful adjuvants. Memcine is managing patent applications on Immunoplex™ in collaboration with the University of Iowa Research Foundation.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form 10-K for the year ended December 31, 2014.

Financial Condition and Changes in Financial Condition

Overall Operating Results:

Comparison of the Three Months Ended June 30, 2015 with the Three Months Ended June 30, 2014

Net Sales. For the three months ended June 30, 2015 and 2014, sales were $0. The lack of revenues is due to the Company continuing to develop technologies in the health field.

General and Administrative Expenses. Our general and administrative expenses increased to $759,476 for the three months ended June 30, 2015 from $252,565 for the three months ended June 30, 2014. The increase was mainly due to an increase in stock-based compensation for professional and consulting fees.

Other Income (Expense). For the three months ended June 30, 2015, other expense was $265,808, compared to $895,811 for the three months ended June 30, 2014. The decrease in other expense was primarily due to decreased interest expense because of the reduction of debt discounts.

Net Loss. The Company’s net loss was $1,003,023 and $1,148,076 for the three months ended June 30, 2015 and 2014, respectively. The increase was due to increased expenses noted above.

Comparison of the Six Months Ended June 30, 2015 with the Six Months Ended June 30, 2014

Net Sales. For the six months ended June 30, 2015 and 2014, sales were $0. The lack of revenues is due to the Company continuing to develop technologies in the health field.

General and Administrative Expenses. Our general and administrative expenses increased to $1,409,011 for the six months ended June 30, 2015 from $346,409 for the six months ended June 30, 2014. The increase was mainly due to an increase in stock based compensation for professional and consulting fees.

Other Income (Expense). For the six months ended June 30, 2015, other expense was $547,619, compared to $914,549 for the six months ended June 30, 2014. The decrease in other expense was primarily due to decreased interest expense because of the reduction of debt discounts.

Net Loss. The Company’s net loss was $1,964,358 and $1,260,958 for the six months ended June 30, 2015 and 2014, respectively. The increase was due to increased expenses noted above.

Liquidity and Capital Resources:

The Company had $1,026,224 in cash as of June 30, 2015. The Company has negative working capital of $3.3 million and total stockholders’ equity of $3.6 million as of June 30, 2015. For the six months ended June 30, 2015, the Company has experienced recurring losses from operations and may not have enough cash and working capital to fund its operations beyond the very near term, which raises substantial doubt about our ability to continue as a going concern. Management has made a similar note in the financial statements. The Company anticipates it will need approximately $2,950,000 for the next twelve months to fund operations. We may be required to seek additional capital by selling debt or equity securities, selling assets, or otherwise be required to bring cash flows in balance when we approach a condition of cash insufficiency. The sale of additional equity or debt securities, if accomplished, may result in dilution to our then shareholders. We provide no assurance that financing will be available in amounts or on terms acceptable to us, or at all.

Cash Flows for the six months ended June 30, 2015 and 2014

Cash Flows from Operating Activities. The Company had net cash used in operating activities of $884,620 and $334,879 for the six months ended June 30, 2015 and 2014, respectively. The increase in net cash used is related to the increase in consulting and professional fees incurred during the six months ended June 30, 2015 compared to the six months ended June 30, 2014.

Cash Flows from Investing Activities. The Company had net cash used by investing activities of $5,524 for the six months ended June 30, 2015 compared to net cash used of $38,079 in the six months ended June 30, 2014.

Cash Flows from Financing Activities. The Company had net cash provided by financing activities of $1,907,300 for the six months ended June 30, 2015 compared to $363,705 for the six months ended June 30, 2014. The increase in cash provided by financing activities is primarily related proceeds received from the issuance of convertible debentures – related parties.

Off Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Recent Accounting Pronouncements

During the six months ended June 30, 2015, there were no accounting standards and interpretations issued which are expected to have a material impact on the Company’s financial position, operations or cash flows.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “ smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We conducted an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a15(e) and 15d15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of June 30, 2015 that our disclosure controls and procedures were not effective at ensuring that the material information required to be disclosed in the Exchange Act reports is recorded, processed, summarized and reported as required in applicable SEC rules and forms, due to the fact that our Chief Executive Officer is also our sole board member. Through the use of external consultants and the review process, management believes that the financial statements and other information presented herewith are materially correct.

Changes in Internal Control over Financial Reporting

During the quarter ended June 30, 2015, there were no changes in our internal control over financial reporting identified in connection with management’s evaluation of the effectiveness of our internal control over the financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

Neither the Company nor its property is a party to any pending legal proceeding.

Item 1A. Risk Factors

Smaller reporting companies are not required to provide disclosure pursuant to this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number		Name of Exhibit

31.1		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.(1)

31.2		Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.(1)

32.1		Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002. (1)

101**		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Stockholders’ Equity, (iv) the Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements, tagged as blocks of text. (2)

_________________

(1)	Filed herewith.

(2)	Users of this data are advised that pursuant to Rule 406T of Regulation S-T, this XBRL information is being furnished and not filed herewith for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and Sections 11 or 12 of the Securities Act of 1933, as amended, and is not to be incorporated by reference into any filing, or part of any registration statement or prospectus, of Spotlight Innovation Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

	SPOTLIGHT INNOVATION INC.

Dated: August 19, 2015	By:	/s/ Cris Grunewald
		Cris Grunewald
		President/Chief Executive Officer, Director


	By:	/s/ David F. Hostelley
		David F. Hostelley Chief Financial Officer

Attached files

Stock widget

Investing forum

Spotlight Innovation Inc. Reports